PharmaSignal Regulatory Updateshttps://pharmasignal.io/articles/Evidence-led updates from FDA, EMA, MHRA and Health Canada.en-usFDA Approves First Treatment for MCT8 Deficiencyhttps://pharmasignal.io/articles/fda/2026-09-29/fda-approves-first-treatment-for-mct8-deficiency-71d903bc/https://pharmasignal.io/articles/fda/2026-09-29/fda-approves-first-treatment-for-mct8-deficiency-71d903bc/Tue, 29 Sep 2026 00:00:00 GMTFDAFDA Intends to Evaluate Changes to the PMTA Regulatory Frameworkhttps://pharmasignal.io/articles/fda/2026-09-29/fda-intends-to-evaluate-changes-to-the-pmta-regulatory-framework-a7df5d78/https://pharmasignal.io/articles/fda/2026-09-29/fda-intends-to-evaluate-changes-to-the-pmta-regulatory-framework-a7df5d78/Tue, 29 Sep 2026 00:00:00 GMTFDAFederal Court Enters Consent Decree Against Gold Star Distribution, Inc.https://pharmasignal.io/articles/fda/2026-09-23/federal-court-enters-consent-decree-against-gold-star-distribution-inc-629808c1/https://pharmasignal.io/articles/fda/2026-09-23/federal-court-enters-consent-decree-against-gold-star-distribution-inc-629808c1/Wed, 23 Sep 2026 00:00:00 GMTFDAMHRA approves lurbinectedin for adults with extensive‑stage small cell lung cancerhttps://pharmasignal.io/articles/mhra/2026-09-23/mhra-approves-lurbinectedin-for-adults-with-extensive-stage-small-cell-lung-cancer-cd565590/https://pharmasignal.io/articles/mhra/2026-09-23/mhra-approves-lurbinectedin-for-adults-with-extensive-stage-small-cell-lung-cancer-cd565590/Wed, 23 Sep 2026 00:00:00 GMTMHRACHMP meeting highlights 14–17 September 2026https://pharmasignal.io/articles/ema/2026-09-18/chmp-meeting-highlights-14-17-september-2026-bd2f714a/https://pharmasignal.io/articles/ema/2026-09-18/chmp-meeting-highlights-14-17-september-2026-bd2f714a/Fri, 18 Sep 2026 00:00:00 GMTEMAFDA approves first gene therapy for pediatric Sanfilippo syndrome Type Ahttps://pharmasignal.io/articles/fda/2026-09-17/fda-approves-first-gene-therapy-for-pediatric-sanfilippo-syndrome-type-a-1b98bdc8/https://pharmasignal.io/articles/fda/2026-09-17/fda-approves-first-gene-therapy-for-pediatric-sanfilippo-syndrome-type-a-1b98bdc8/Thu, 17 Sep 2026 00:00:00 GMTFDAFDA Launches Expedited IND Pilot, Begins Accepting Applicationshttps://pharmasignal.io/articles/fda/2026-09-15/fda-launches-expedited-ind-pilot-begins-accepting-applications-bd91a2c5/https://pharmasignal.io/articles/fda/2026-09-15/fda-launches-expedited-ind-pilot-begins-accepting-applications-bd91a2c5/Tue, 15 Sep 2026 00:00:00 GMTFDAIndependent Commission publishes blueprint to accelerate safe AI adoption in UK healthcarehttps://pharmasignal.io/articles/mhra/2026-09-10/independent-commission-publishes-blueprint-to-accelerate-safe-ai-adoption-in-uk-healthcare-9c7f6f90/https://pharmasignal.io/articles/mhra/2026-09-10/independent-commission-publishes-blueprint-to-accelerate-safe-ai-adoption-in-uk-healthcare-9c7f6f90/Thu, 10 Sep 2026 00:00:00 GMTMHRAFDA Grants Accelerated Approval to a New Breast Cancer Treatmenthttps://pharmasignal.io/articles/fda/2026-09-04/fda-grants-accelerated-approval-to-a-new-breast-cancer-treatment-c2c706d0/https://pharmasignal.io/articles/fda/2026-09-04/fda-grants-accelerated-approval-to-a-new-breast-cancer-treatment-c2c706d0/Fri, 04 Sep 2026 00:00:00 GMTFDAFDA Approves First Drug to Treat Alexander Diseasehttps://pharmasignal.io/articles/fda/2026-09-03/fda-approves-first-drug-to-treat-alexander-disease-5a37c686/https://pharmasignal.io/articles/fda/2026-09-03/fda-approves-first-drug-to-treat-alexander-disease-5a37c686/Thu, 03 Sep 2026 00:00:00 GMTFDAEMA launches voluntary data submission pilot to advance innovative alternatives to animal testinghttps://pharmasignal.io/articles/ema/2026-09-01/ema-launches-voluntary-data-submission-pilot-to-advance-innovative-alternatives-to-animal--2c8ea0d6/https://pharmasignal.io/articles/ema/2026-09-01/ema-launches-voluntary-data-submission-pilot-to-advance-innovative-alternatives-to-animal--2c8ea0d6/Tue, 01 Sep 2026 00:00:00 GMTEMAMHRA concludes review of Avacopan Vifor following reassessment of benefit-risk balancehttps://pharmasignal.io/articles/mhra/2026-09-01/mhra-concludes-review-of-avacopan-vifor-following-reassessment-of-benefit-risk-balance-c5048418/https://pharmasignal.io/articles/mhra/2026-09-01/mhra-concludes-review-of-avacopan-vifor-following-reassessment-of-benefit-risk-balance-c5048418/Tue, 01 Sep 2026 00:00:00 GMTMHRAMHRA regulatory reform amendments tabled in Government’s Health Billhttps://pharmasignal.io/articles/mhra/2026-09-01/mhra-regulatory-reform-amendments-tabled-in-government-s-health-bill-4df2c6f9/https://pharmasignal.io/articles/mhra/2026-09-01/mhra-regulatory-reform-amendments-tabled-in-government-s-health-bill-4df2c6f9/Tue, 01 Sep 2026 00:00:00 GMTMHRASummary Basis of Decision for Leqembihttps://pharmasignal.io/articles/hc/2026-08-31/summary-basis-of-decision-for-leqembi-9180b094/https://pharmasignal.io/articles/hc/2026-08-31/summary-basis-of-decision-for-leqembi-9180b094/Mon, 31 Aug 2026 00:00:00 GMTHealth CanadaFDA approves first‑in‑class Mimrylo (rusfertide) for polycythemia verahttps://pharmasignal.io/articles/fda/2026-08-29/fda-approves-first-in-class-mimrylo-rusfertide-for-polycythemia-vera-b8d53607/https://pharmasignal.io/articles/fda/2026-08-29/fda-approves-first-in-class-mimrylo-rusfertide-for-polycythemia-vera-b8d53607/Sat, 29 Aug 2026 00:00:00 GMTFDAFDA Approves First Oral Drug for Dermatomyositis in Adultshttps://pharmasignal.io/articles/fda/2026-08-27/fda-approves-first-oral-drug-for-dermatomyositis-in-adults-2f11a8e1/https://pharmasignal.io/articles/fda/2026-08-27/fda-approves-first-oral-drug-for-dermatomyositis-in-adults-2f11a8e1/Thu, 27 Aug 2026 00:00:00 GMTFDAFDA Issues EUA for Generic Ivermectin Injection to Prevent New World Screwworm in Cattlehttps://pharmasignal.io/articles/fda/2026-08-27/fda-issues-eua-for-generic-ivermectin-injection-to-prevent-new-world-screwworm-in-cattle-92911550/https://pharmasignal.io/articles/fda/2026-08-27/fda-issues-eua-for-generic-ivermectin-injection-to-prevent-new-world-screwworm-in-cattle-92911550/Thu, 27 Aug 2026 00:00:00 GMTFDAFDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancerhttps://pharmasignal.io/articles/fda/2026-08-26/fda-approves-first-in-class-targeted-therapy-for-metastatic-pancreatic-cancer-99356a2e/https://pharmasignal.io/articles/fda/2026-08-26/fda-approves-first-in-class-targeted-therapy-for-metastatic-pancreatic-cancer-99356a2e/Wed, 26 Aug 2026 00:00:00 GMTFDAIncreased risk of wear and corrosion identified with certain cobalt chrome modular neck hip replacementshttps://pharmasignal.io/articles/mhra/2026-08-26/increased-risk-of-wear-and-corrosion-identified-with-certain-cobalt-chrome-modular-neck-hi-fdada7af/https://pharmasignal.io/articles/mhra/2026-08-26/increased-risk-of-wear-and-corrosion-identified-with-certain-cobalt-chrome-modular-neck-hi-fdada7af/Wed, 26 Aug 2026 00:00:00 GMTMHRAFDA Authorizes First Wearable Device That Continuously Monitors Both Ketone Levels and Blood Sugarhttps://pharmasignal.io/articles/fda/2026-08-25/fda-authorizes-first-wearable-device-that-continuously-monitors-both-ketone-levels-and-blo-ff25f530/https://pharmasignal.io/articles/fda/2026-08-25/fda-authorizes-first-wearable-device-that-continuously-monitors-both-ketone-levels-and-blo-ff25f530/Tue, 25 Aug 2026 00:00:00 GMTFDAMHRA sets out position on regulation of microbiome-based medicinal productshttps://pharmasignal.io/articles/mhra/2026-08-18/mhra-sets-out-position-on-regulation-of-microbiome-based-medicinal-products-0872e65c/https://pharmasignal.io/articles/mhra/2026-08-18/mhra-sets-out-position-on-regulation-of-microbiome-based-medicinal-products-0872e65c/Tue, 18 Aug 2026 00:00:00 GMTMHRAQualifying notice for Ojemdahttps://pharmasignal.io/articles/hc/2026-08-18/qualifying-notice-for-ojemda-0e34fb64/https://pharmasignal.io/articles/hc/2026-08-18/qualifying-notice-for-ojemda-0e34fb64/Tue, 18 Aug 2026 00:00:00 GMTHealth CanadaMHRA advises quarantine of medical devices supplied without appropriate conformity markingshttps://pharmasignal.io/articles/mhra/2026-08-14/mhra-advises-quarantine-of-medical-devices-supplied-without-appropriate-conformity-marking-2eccdc16/https://pharmasignal.io/articles/mhra/2026-08-14/mhra-advises-quarantine-of-medical-devices-supplied-without-appropriate-conformity-marking-2eccdc16/Fri, 14 Aug 2026 00:00:00 GMTMHRAVimseltinib (romvimza) approved for use in adults to treat tenosynovial giant cell tumourshttps://pharmasignal.io/articles/mhra/2026-08-14/vimseltinib-romvimza-approved-for-use-in-adults-to-treat-tenosynovial-giant-cell-tumours-80b54134/https://pharmasignal.io/articles/mhra/2026-08-14/vimseltinib-romvimza-approved-for-use-in-adults-to-treat-tenosynovial-giant-cell-tumours-80b54134/Fri, 14 Aug 2026 00:00:00 GMTMHRAUK first in Europe to authorise orforglipron for weight management and type 2 diabeteshttps://pharmasignal.io/articles/mhra/2026-08-10/uk-first-in-europe-to-authorise-orforglipron-for-weight-management-and-type-2-diabetes-362e51b9/https://pharmasignal.io/articles/mhra/2026-08-10/uk-first-in-europe-to-authorise-orforglipron-for-weight-management-and-type-2-diabetes-362e51b9/Mon, 10 Aug 2026 00:00:00 GMTMHRAMHRA approves remibrutinib for adults with chronic spontaneous urticariahttps://pharmasignal.io/articles/mhra/2026-08-06/mhra-approves-remibrutinib-for-adults-with-chronic-spontaneous-urticaria-e5b46ba7/https://pharmasignal.io/articles/mhra/2026-08-06/mhra-approves-remibrutinib-for-adults-with-chronic-spontaneous-urticaria-e5b46ba7/Thu, 06 Aug 2026 00:00:00 GMTMHRAThousands of patients to benefit from new daily pill for serious heart condition following co‑ordinated MHRA and NICE decisionshttps://pharmasignal.io/articles/mhra/2026-07-30/thousands-of-patients-to-benefit-from-new-daily-pill-for-serious-heart-condition-following-078b3fa8/https://pharmasignal.io/articles/mhra/2026-07-30/thousands-of-patients-to-benefit-from-new-daily-pill-for-serious-heart-condition-following-078b3fa8/Thu, 30 Jul 2026 00:00:00 GMTMHRAMHRA clarifies regulatory status of ambient voice technologies used in the NHShttps://pharmasignal.io/articles/mhra/2026-07-29/mhra-clarifies-regulatory-status-of-ambient-voice-technologies-used-in-the-nhs-91967e69/https://pharmasignal.io/articles/mhra/2026-07-29/mhra-clarifies-regulatory-status-of-ambient-voice-technologies-used-in-the-nhs-91967e69/Wed, 29 Jul 2026 00:00:00 GMTMHRACHMP issues July 2026 meeting highlightshttps://pharmasignal.io/articles/ema/2026-07-24/chmp-issues-july-2026-meeting-highlights-05987539/https://pharmasignal.io/articles/ema/2026-07-24/chmp-issues-july-2026-meeting-highlights-05987539/Fri, 24 Jul 2026 00:00:00 GMTEMAHealth Canada launches draft guidance on Ministerial Reliance Order for human and veterinary drug submissionshttps://pharmasignal.io/articles/hc/2026-07-16/health-canada-launches-draft-guidance-on-ministerial-reliance-order-for-human-and-veterina-e3fb5873/https://pharmasignal.io/articles/hc/2026-07-16/health-canada-launches-draft-guidance-on-ministerial-reliance-order-for-human-and-veterina-e3fb5873/Thu, 16 Jul 2026 00:00:00 GMTHealth CanadaPRAC meeting highlights 6–9 July 2026https://pharmasignal.io/articles/ema/2026-07-10/prac-meeting-highlights-6-9-july-2026-4eb224be/https://pharmasignal.io/articles/ema/2026-07-10/prac-meeting-highlights-6-9-july-2026-4eb224be/Fri, 10 Jul 2026 00:00:00 GMTEMACHMP meeting highlights 22‑25 June 2026https://pharmasignal.io/articles/ema/2026-06-26/chmp-meeting-highlights-22-25-june-2026-88516a06/https://pharmasignal.io/articles/ema/2026-06-26/chmp-meeting-highlights-22-25-june-2026-88516a06/Fri, 26 Jun 2026 00:00:00 GMTEMASummary Basis of Decision for Voxzogohttps://pharmasignal.io/articles/hc/2026-06-05/summary-basis-of-decision-for-voxzogo-4f467e23/https://pharmasignal.io/articles/hc/2026-06-05/summary-basis-of-decision-for-voxzogo-4f467e23/Fri, 05 Jun 2026 00:00:00 GMTHealth CanadaSummary Basis of Decision for Eydenzelthttps://pharmasignal.io/articles/hc/2026-06-05/summary-basis-of-decision-for-eydenzelt-4f8acc27/https://pharmasignal.io/articles/hc/2026-06-05/summary-basis-of-decision-for-eydenzelt-4f8acc27/Fri, 05 Jun 2026 00:00:00 GMTHealth CanadaSummary Basis of Decision for Redemplohttps://pharmasignal.io/articles/hc/2026-06-05/summary-basis-of-decision-for-redemplo-35e98aee/https://pharmasignal.io/articles/hc/2026-06-05/summary-basis-of-decision-for-redemplo-35e98aee/Fri, 05 Jun 2026 00:00:00 GMTHealth CanadaSummary Basis of Decision for Ziiherahttps://pharmasignal.io/articles/hc/2026-06-05/summary-basis-of-decision-for-ziihera-eb261d27/https://pharmasignal.io/articles/hc/2026-06-05/summary-basis-of-decision-for-ziihera-eb261d27/Fri, 05 Jun 2026 00:00:00 GMTHealth CanadaSummary Basis of Decision for Tryngolzahttps://pharmasignal.io/articles/hc/2026-06-05/summary-basis-of-decision-for-tryngolza-4b66764a/https://pharmasignal.io/articles/hc/2026-06-05/summary-basis-of-decision-for-tryngolza-4b66764a/Fri, 05 Jun 2026 00:00:00 GMTHealth CanadaEMA, AMA and African regulatory authorities join forces on Ebola outbreak responsehttps://pharmasignal.io/articles/ema/2026-06-03/ema-ama-and-african-regulatory-authorities-join-forces-on-ebola-outbreak-response-2c2dc56c/https://pharmasignal.io/articles/ema/2026-06-03/ema-ama-and-african-regulatory-authorities-join-forces-on-ebola-outbreak-response-2c2dc56c/Wed, 03 Jun 2026 00:00:00 GMTEMAETF recommends updating COVID-19 vaccines to target XFG varianthttps://pharmasignal.io/articles/ema/2026-05-29/etf-recommends-updating-covid-19-vaccines-to-target-xfg-variant-992480af/https://pharmasignal.io/articles/ema/2026-05-29/etf-recommends-updating-covid-19-vaccines-to-target-xfg-variant-992480af/Fri, 29 May 2026 00:00:00 GMTEMAGuidance on nitrosamine impurities in medications updatedhttps://pharmasignal.io/articles/hc/2026-05-29/guidance-on-nitrosamine-impurities-in-medications-updated-a2c75e4e/https://pharmasignal.io/articles/hc/2026-05-29/guidance-on-nitrosamine-impurities-in-medications-updated-a2c75e4e/Fri, 29 May 2026 00:00:00 GMTHealth CanadaEMA CHMP opinion recommends authorisation of Jascayd (nerandomilast) for IPF and PPFhttps://pharmasignal.io/articles/ema/2026-05-22/ema-chmp-opinion-recommends-authorisation-of-jascayd-nerandomilast-for-ipf-and-ppf-d0147c52/https://pharmasignal.io/articles/ema/2026-05-22/ema-chmp-opinion-recommends-authorisation-of-jascayd-nerandomilast-for-ipf-and-ppf-d0147c52/Fri, 22 May 2026 00:00:00 GMTEMAEMA actively monitoring cruise ship Hantavirus outbreakhttps://pharmasignal.io/articles/ema/2026-05-12/ema-actively-monitoring-cruise-ship-hantavirus-outbreak-fc1f864c/https://pharmasignal.io/articles/ema/2026-05-12/ema-actively-monitoring-cruise-ship-hantavirus-outbreak-fc1f864c/Tue, 12 May 2026 00:00:00 GMTEMAEMA recommends authorisation of first veterinary vaccine using RNA technologyhttps://pharmasignal.io/articles/ema/2026-04-21/ema-recommends-authorisation-of-first-veterinary-vaccine-using-rna-technology-09db370f/https://pharmasignal.io/articles/ema/2026-04-21/ema-recommends-authorisation-of-first-veterinary-vaccine-using-rna-technology-09db370f/Tue, 21 Apr 2026 00:00:00 GMTEMAFinal notice: Classification of topical products containing human‑derived exosomes, extracellular vesicles, or cell‑conditioned mediahttps://pharmasignal.io/articles/hc/2026-04-11/final-notice-classification-of-topical-products-containing-human-derived-exosomes-extracel-a358b213/https://pharmasignal.io/articles/hc/2026-04-11/final-notice-classification-of-topical-products-containing-human-derived-exosomes-extracel-a358b213/Sat, 11 Apr 2026 00:00:00 GMTHealth CanadaEMA consults on virtual control groups to help reduce animal use in medicines developmenthttps://pharmasignal.io/articles/ema/2026-03-31/ema-consults-on-virtual-control-groups-to-help-reduce-animal-use-in-medicines-development-2573bb2e/https://pharmasignal.io/articles/ema/2026-03-31/ema-consults-on-virtual-control-groups-to-help-reduce-animal-use-in-medicines-development-2573bb2e/Tue, 31 Mar 2026 00:00:00 GMTEMAEMA recommends restricting use of Tecovirimat SIGAhttps://pharmasignal.io/articles/ema/2026-03-27/ema-recommends-restricting-use-of-tecovirimat-siga-a993aadf/https://pharmasignal.io/articles/ema/2026-03-27/ema-recommends-restricting-use-of-tecovirimat-siga-a993aadf/Fri, 27 Mar 2026 00:00:00 GMTEMA